title: Reputation and precedent in the bevacizumab decision.
authors.affiliation: Department of Government, Harvard University, Cambridge, MA, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Carpenter
authors.forename: Aaron S
authors.initials: AS
authors.lastname: Kesselheim
authors.forename: Steven
authors.initials: S
authors.lastname: Joffe
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D017277:Drug Approval; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab